Treatment of hemophilic arthropathy by immunomodulatory extracellular vesicle delivered by liposome hybrid nanoparticles
Source abstract
Abstract
In individuals afflicted with hemophilia, characterized by a deficiency of coagulation factor VIII (FVIII), the occurrence of spontaneous recurrent intra-articular hemorrhage precipitates the emergence of hemophilic arthropathy (HA). Although clotting factor replacement therapy reduces joint bleeding clinically, clotting factors need to be injected frequently due to the rapid diffusion of the drug. Hence, a novel drug delivery approach may be developed to improve the drug therapy. Platelet-derived extracellular vesicles (PEVs) are known to possess anti-inflammatory and hemostatic properties and could be used as a potential HA therapy. In this study, we constructed a PEV-LS@FVIII nanotherapeutic system by combining thioketal (TK), liposomes (LS), and FVIII to form the LS@FVIII complexes, and then hybridizing PEV with LS@FVIII. Our results demonstrated that PEV-LS@FVIII could efficiently facilitate FVIII delivery and specifically target the injured knee joint. Both in vitro and in vivo studies showed a reduction in the M1 phenotype of macrophages and an enhancement of the M2 phenotype, compared to FVIII free control. Furthermore, PEV-LS@FVIII appeared to alleviate HA-induced cartilage damage. In conclusion, our findings demonstrate that PEV-LS@FVIII could delay the progression of HA by targeting bleeding joints, modulating macrophage polarization to suppress inflammation, and mitigating cartilage damage. • The PEV-LS@FVIII nanotherapeutic system improves the delivery efficiency of FVIII by targeting the injured knee joint. • The PEV-LS@FVIII shows the ability to regulate macrophage polarization in HA mice. • PEV-LS@FVIII attenuates HA-induced cartilage damage and has potential in delaying HA progression.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hemophilia Treatment and Research · Platelet Disorders and Treatments · Blood Coagulation and Thrombosis Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The past and future of haemophilia: diagnosis, treatments, and its complications10.1016/S0140-6736(15)01123-X ↗
2. Current therapy for rare factor deficiencies10.1046/j.1365-2516.2001.00100.x ↗
3. Haemophilia in Spain10.1111/j.1365-2516.2009.02001.x ↗
4. The growing complexity of platelet aggregation10.1182/blood-2006-12-027698 ↗
5. Haemophilia care in Europe: the ESCHQoL study10.1111/j.1365-2516.2012.02847.x ↗
6. Pathological mechanism of joint destruction in haemophilic arthropathy10.1007/s11033-020-06052-8 ↗
7. Pathophysiology of hemophilic arthropathy and potential targets for therapy10.1016/j.phrs.2016.11.032 ↗
8. Maladaptive lymphangiogenesis is associated with synovial iron accumulation and delayed clearance in factor VIII-deficient mice after induced hemarthrosis10.1016/j.jtha.2023.04.022 ↗
9. Haemophilia10.1038/s41572-021-00278-x ↗
10. Hemarthrosis in hemophilic mice results in alterations in M1-M2 monocyte/macrophage polarization10.1016/j.thromres.2013.10.039 ↗
11. Prospective evaluation of treatment regimens, efficacy and safety of a recombinant factor VIII concentrate in haemophilia A: the German EffeKt study10.1111/hae.12941 ↗
12. Immunogenicity of long-lasting recombinant factor VIII products10.1016/j.cellimm.2015.12.006 ↗
13. Hemophilic arthropathy: considerations in management10.7547/87507315-91-8-406 ↗
14. Targeted drug delivery: trends and perspectives10.2174/1567201818666210609161301 ↗
15. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models10.1182/blood-2012-01-407494 ↗
16. Concept and clinical evaluation of carrier-mediated anticancer agents10.1634/theoncologist.2007-0180 ↗
17. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine
18. Lipid-polymer hybrid nanosystems: a rational fusion for advanced therapeutic delivery10.3390/jfb14090437 ↗
19. Extracellular vesicles from immortalized cardiosphere-derived cells attenuate arrhythmogenic cardiomyopathy in desmoglein-2 mutant mice10.1093/eurheartj/ehab419 ↗
20. Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles10.1002/jev2.12134 ↗
21. Extracellular vesicles from human umbilical cord blood ameliorate bone loss in senile osteoporotic mice10.1016/j.metabol.2019.01.009 ↗
22. Bacterial extracellular vesicle-coated multi-antigenic nanovaccines protect against drug-resistant Staphylococcus aureus infection by modulating antigen processing and presentation pathways10.7150/thno.44564 ↗
23. Platelet-derived- extracellular vesicles promote hemostasis and prevent the development of hemorrhagic shock10.1038/s41598-019-53724-y ↗
24. Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery10.18632/oncotarget.27223 ↗
25. Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin10.1182/blood-2015-04-640300 ↗
26. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets10.1160/TH06-06-0313 ↗
27. Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine10.1016/j.blre.2014.04.002 ↗
28. Nanoparticle biointerfacing by platelet membrane cloaking10.1038/nature15373 ↗
29. Platelet-released extracellular vesicles: the effects of thrombin activation10.1007/s00018-022-04222-4 ↗
30. Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy10.1016/j.jconrel.2020.11.064 ↗
31. Calming cytokine storm in pneumonia by targeted delivery of TPCA-1 using platelet-derived extracellular vesicles10.1016/j.matt.2020.05.017 ↗
32. Platelet-derived exosomes promote neutrophil extracellular trap formation during septic shock10.1186/s13054-020-03082-3 ↗
33. Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells10.4049/jimmunol.1002788 ↗
34. The anti-inflammatory effects of platelet-derived microparticles in human plasmacytoid dendritic cells involve liver X receptor activation10.3324/haematol.2015.135459 ↗
35. A natural hydrogel complex improves intervertebral disc degeneration by correcting fatty acid metabolism and inhibiting nucleus pulposus cell pyroptosis
36. Platelet-derived exosomes alleviate knee osteoarthritis by attenuating cartilage degeneration and subchondral bone loss10.1177/03635465231188122 ↗
37. Extracellular vesicles as drug delivery systems: lessons from the liposome field10.1016/j.jconrel.2014.07.049 ↗
38. Extracellular vesicles for drug delivery10.1016/j.addr.2016.02.006 ↗
39. Liposomes as biocompatible and smart delivery systems - the current state10.1016/j.cis.2022.102757 ↗
40. Extracellular vesicle-based hybrid systems for advanced drug delivery10.3390/pharmaceutics14020267 ↗
41. Exosomes derived from platelet-rich plasma administration in site mediate cartilage protection in subtalar osteoarthritis10.1186/s12951-022-01245-8 ↗
42. ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling10.1186/s12951-022-01435-4 ↗
43. Annexin V-modified platelet-biomimetic nanomedicine for targeted therapy of acute ischemic stroke10.1002/adhm.202200416 ↗
44. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice10.1182/blood.2019003824 ↗
45. Glucose-responsive biomimetic nanoreactor in bacterial cellulose hydrogel for antibacterial and hemostatic therapies10.1016/j.carbpol.2022.119615 ↗
46. Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice10.1182/blood.2021013119 ↗
47. ROS responsive nanoparticles encapsulated with natural medicine remodel autophagy homeostasis in breast cancer10.1021/acsami.3c03068 ↗
48. A new biosafe reactive oxygen species (ROS)-responsive nanoplatform for drug delivery10.1039/C5RA25913D ↗
49. Reactive oxygen species-sensitive thioketal-linked mesoporous silica nanoparticles as drug carrier for effective antibacterial activity
50. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy10.1111/j.1538-7836.2010.03962.x ↗
51. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia10.1056/NEJMoa067659 ↗
52. Prophylaxis with factor concentrates in preventing hemophilic arthropathy10.1097/00043426-199123000-00006 ↗
53. Liposome: classification, preparation, and applications10.1186/1556-276X-8-102 ↗
54. Liposome composition in drug delivery design, synthesis, characterization, and clinical application10.1016/j.addr.2021.113851 ↗
55. Binding of factor VIII to lipid nanodiscs increases its clotting function in a mouse model of hemophilia A10.4172/2155-9864.1000325 ↗
56. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue10.1111/j.1365-2516.2009.02155.x ↗
57. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A10.1111/j.1538-7836.2008.02856.x ↗
58. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes10.1182/blood-2006-03-008276 ↗
59. Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients10.1111/j.1365-2141.2012.09115.x ↗
60. Lipid-bound factor Xa regulates tissue factor activity10.1021/bi700136a ↗
61. Extracellular vesicles and nanoparticles: emerging complexities10.1016/j.tcb.2023.01.002 ↗
62. Extracellular vesicle-based therapeutics: extracellular vesicles as therapeutic targets and agents10.1016/j.pharmthera.2023.108352 ↗
63. Reshaping the inflammatory environment in rheumatoid arthritis joints by targeting delivery of berberine with platelet-derived extracellular vesicles10.1002/anbr.202100115 ↗
64. Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer10.1002/cyto.a.20354 ↗
65. Mildly oxidized HDL decrease agonist-induced platelet aggregation and release of pro-coagulant platelet extracellular vesicles10.1016/j.jsbmb.2016.05.003 ↗
66. Platelet extracellular vesicles as biomarkers for arterial thrombosis10.1080/09537104.2016.1254174 ↗
67. Liposomal drug delivery systems: from concept to clinical applications10.1016/j.addr.2012.09.037 ↗
68. Procoagulant microparticles: disrupting the vascular homeostasis equation?10.1161/01.ATV.0000246775.14471.26 ↗
69. Platelet-derived extracellular vesicles released after trauma promote hemostasis and contribute to DVT in mice10.1111/jth.14563 ↗
70. Neoangiogenesis contributes to the development of hemophilic synovitis10.1182/blood-2010-05-284653 ↗
71. Haemoglobin-derived iron-dependent hydroxyl radical formation in blood-induced joint damage: an in vitro study10.1093/rheumatology/keg220 ↗
72. The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis10.3389/fimmu.2022.867260 ↗
73. Triamcinolone-gold nanoparticles repolarize synoviocytes and macrophages in an inflamed synovium10.1021/acsami.0c09842 ↗
74. PAR2 promotes M1 macrophage polarization and inflammation via FOXO1 pathway10.1002/jcb.28260 ↗
75. Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathology10.1136/annrheumdis-2015-208268 ↗
76. Factor Xa induces pro-inflammatory cytokine expression in RAW 264.7 macrophages via protease-activated receptor-2 activation
77. Microparticles from apoptotic platelets promote resident macrophage differentiation10.1038/cddis.2011.94 ↗
78. Platelet microparticles reprogram macrophage gene expression and function10.1160/th15-05-0389 ↗
79. Immunometabolism governs dendritic cell and macrophage function10.1084/jem.20151570 ↗
80. Cellular metabolism and macrophage functional polarization10.3109/08830185.2014.969421 ↗
81. Lipid metabolism in regulation of macrophage functions10.1016/j.tcb.2020.09.006 ↗
82. Choline uptake and metabolism modulate macrophage IL-1beta and IL-18 production10.1016/j.cmet.2019.03.011 ↗
83. Oxysterol restraint of cholesterol synthesis prevents AIM2 inflammasome activation10.1016/j.cell.2017.09.029 ↗
84. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals10.1038/nature08938 ↗
85. More than just protein building blocks: how amino acids and related metabolic pathways fuel macrophage polarization10.1111/febs.15715 ↗
86. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide10.1073/pnas.82.22.7738 ↗
87. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization10.1016/j.immuni.2015.02.005 ↗
88. Glutathione metabolism in resting and phagocytizing peritoneal macrophages10.1016/S0021-9258(19)68139-1 ↗
89. Hemophilic arthropathy: current knowledge and future perspectives10.1111/jth.15444 ↗
90. Membrane-associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1 alpha transgenic mice10.4049/jimmunol.172.1.577 ↗
91. Iron deposits and catabolic properties of synovial tissue from patients with haemophilia10.1302/0301-620X.80B3.0800540 ↗
92. Inflammation is key to hemophilic arthropathy10.1182/blood-2015-09-665091 ↗
93. Exosomes derived from platelet-rich plasma present a novel potential in alleviating knee osteoarthritis by promoting proliferation and inhibiting apoptosis of chondrocyte via Wnt/beta-catenin signaling pathway10.1186/s13018-019-1529-7 ↗
94. Platelet-derived microparticles mediate the intra-articular homing of mesenchymal stem cells in early-stage cartilage lesions10.1089/scd.2019.0137 ↗
95. Characterization and chondroprotective effects of extracellular vesicles from plasma- and serum-based autologous blood-derived products for osteoarthritis therapy10.3389/fbioe.2020.584050 ↗
96. TNF-alpha/TNF-R system may represent a crucial mediator of proliferative synovitis in hemophilia A10.3390/jcm8070939 ↗
97. Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression10.1074/jbc.M512624200 ↗
98. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-1710.1093/rheumatology/ken363 ↗
99. Mechanoelectronic stimulation of autologous extracellular vesicle biosynthesis implant for gut microbiota modulation10.1038/s41467-024-47710-w ↗
100. Liposomes: advancements and innovation in the manufacturing process10.1016/j.addr.2020.07.002 ↗